SMBC Nikko Securities Takes 14.79% Stake in Oncolytics Biopharma (4588) | Large Shareholding Report

A large shareholding report (EDINET filing) reveals that SMBC Nikko Securities Co., Ltd. has raised its stake in Oncolytics Biopharma Inc. (4588) to 14.79%. The company is a biotechnology firm focused on developing innovative pharmaceutical products including gene therapy and immunotherapy targeting cancer treatment. The 14.79% shareholding represents a substantial stake, positioning the investor as a major shareholder in the company's issued shares.

SMBC Nikko Securities, part of the Sumitomo Mitsui Financial Group, filed this report on August 12, 2025. No prior disclosure by the same filer regarding this stock was found within the preceding 400 days, suggesting this represents a substantial new acquisition or significant resumption of holdings. The estimated acquisition amount totals approximately ¥2.73 billion, reflecting capital inflow into the high-growth biotech sector focused on oncology therapeutics.

A major securities firm's capital commitment to a large biotech venture represents a noteworthy market development. Through this acquisition, SMBC Nikko Securities has established a capital-based relationship with Oncolytics Biopharma.
*Speculation: The strategic investment in a biotechnology company with innovative cancer treatment pipelines may reflect the mega-banking group's intention to deepen its involvement in cutting-edge medical research and development.